Trial Profile
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms RATE-RA
- Sponsors Roche
- 11 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.